Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world. Neoadjuvant chemotherapy (NAC) has become a standard treatment for patients scheduled for surgical resection, but the high rate of postoperative recurrence is a critical problem. Optimization of NAC is desirable to...

Full description

Bibliographic Details

Published in:	Biomolecules
Main Authors:	Keisuke Takemura, Kyohei Ikeda, Hayato Miyake, Yoshio Sogame, Hiroaki Yasuda, Nobuhiro Okada, Kazumi Iwata, Junichi Sakagami, Kanji Yamaguchi, Yoshito Itoh, Atsushi Umemura
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Subjects:	pancreatic ductal adenocarcinoma neoadjuvant chemotherapy epithelial–mesenchymal transition ML210 gemcitabine
Online Access:	https://www.mdpi.com/2218-273X/15/1/70